Cargando…
Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials
OBJECTIVE—Despite experimental data suggesting a protective effect of peroxisome proliferator–activated receptor-γ agonists with respect to malignancies, results of available epidemiological studies on the incidence of cancer in rosiglitazone-treated patients are not univocal. The aim of this meta-a...
Autores principales: | Monami, Matteo, Lamanna, Caterina, Marchionni, Niccolò, Mannucci, Edoardo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453648/ https://www.ncbi.nlm.nih.gov/pubmed/18375416 http://dx.doi.org/10.2337/dc07-2308 |
Ejemplares similares
-
Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials
por: Monami, Matteo, et al.
Publicado: (2011) -
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
por: Monami, Matteo, et al.
Publicado: (2011) -
Efficacy of Insulin Analogs in Achieving the Hemoglobin A(1c) Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials
por: Giugliano, Dario, et al.
Publicado: (2011) -
Diabetes and Risk of Parkinson’s Disease: A systematic review and meta-analysis
por: Cereda, Emanuele, et al.
Publicado: (2011) -
Metabolic Syndrome and Risk of Cancer: A systematic review and meta-analysis
por: Esposito, Katherine, et al.
Publicado: (2012)